IL216881A - Glucagon compounds affecting gip receptor - Google Patents
Glucagon compounds affecting gip receptorInfo
- Publication number
- IL216881A IL216881A IL216881A IL21688111A IL216881A IL 216881 A IL216881 A IL 216881A IL 216881 A IL216881 A IL 216881A IL 21688111 A IL21688111 A IL 21688111A IL 216881 A IL216881 A IL 216881A
- Authority
- IL
- Israel
- Prior art keywords
- gip receptor
- active glucagon
- glucagon compounds
- compounds
- active
- Prior art date
Links
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18757809P | 2009-06-16 | 2009-06-16 | |
| PCT/US2010/038825 WO2010148089A1 (en) | 2009-06-16 | 2010-06-16 | Gip receptor-active glucagon compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL216881A0 IL216881A0 (en) | 2012-02-29 |
| IL216881A true IL216881A (en) | 2016-08-31 |
Family
ID=43356738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL216881A IL216881A (en) | 2009-06-16 | 2011-12-08 | Glucagon compounds affecting gip receptor |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9150632B2 (enExample) |
| EP (1) | EP2443146B1 (enExample) |
| JP (1) | JP5887265B2 (enExample) |
| KR (1) | KR20120087875A (enExample) |
| CN (1) | CN102459325B (enExample) |
| AU (1) | AU2010260058B2 (enExample) |
| BR (1) | BRPI1014508A2 (enExample) |
| CA (1) | CA2765026A1 (enExample) |
| CL (1) | CL2011003173A1 (enExample) |
| IL (1) | IL216881A (enExample) |
| IN (1) | IN2012DN00377A (enExample) |
| MX (1) | MX2011013625A (enExample) |
| PE (1) | PE20120914A1 (enExample) |
| RU (1) | RU2012101274A (enExample) |
| SG (1) | SG176858A1 (enExample) |
| TW (1) | TWI549687B (enExample) |
| WO (1) | WO2010148089A1 (enExample) |
Families Citing this family (104)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101534846B (zh) | 2005-11-07 | 2014-11-05 | 印第安纳大学研究及科技有限公司 | 显示生理学溶解性和稳定性的胰高血糖素类似物 |
| JP5890085B2 (ja) | 2007-01-05 | 2016-03-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 生理学的ｐＨの緩衝液中で向上した溶解度を示すグルカゴン類縁体 |
| US8454971B2 (en) | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| EP2214691B1 (en) | 2007-10-30 | 2015-09-30 | Indiana University Research and Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| AU2008318986B2 (en) | 2007-10-30 | 2014-12-04 | Indiana University Research And Technology Corporation | Glucagon antagonists |
| EP2676673B1 (en) | 2008-06-17 | 2016-11-16 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| WO2009155257A1 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
| AR072159A1 (es) | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad |
| WO2010071807A1 (en) | 2008-12-19 | 2010-06-24 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| IN2012DN00377A (enExample) | 2009-06-16 | 2015-08-21 | Univ Indiana Res & Tech Corp | |
| AP3329A (en) | 2009-07-13 | 2015-06-30 | Zealand Pharma As | Acylated glucagon analogues |
| EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
| IN2012DN06437A (enExample) | 2010-01-27 | 2015-10-09 | Univ Indiana Res & Tech Corp | |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| WO2011143208A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| KR20130062931A (ko) | 2010-05-13 | 2013-06-13 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 핵 호르몬 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
| US8778872B2 (en) | 2010-06-24 | 2014-07-15 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| KR20140020851A (ko) | 2010-12-22 | 2014-02-19 | 마르카디아 바이오테크, 인코퍼레이트 | Gip 및 glp-1 수용체-활성 글루카곤계 펩타이드를 이용한 대사장애 및 비만의 치료방법 |
| PH12013501215A1 (en) | 2010-12-22 | 2013-11-18 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
| US20140031278A1 (en) * | 2011-03-28 | 2014-01-30 | Novo Nordisk A/S | Novel Glucagon Analogues |
| DK2694095T3 (en) * | 2011-04-05 | 2018-05-28 | Longevity Biotech Inc | COMPOSITIONS COMPREHENSIVE GLUCAGON ANALOGS AND METHODS FOR PREPARING AND USING THE SAME |
| MX391293B (es) | 2011-06-10 | 2025-03-21 | Hanmi Science Co Ltd | DERIVADOs DE OXINTOMODULINA NOVEDOSOS Y COMPOSICION FARMACEUTICA PARA TRATAR LA OBESIDAD QUE COMPRENDE LOS MISMOS. |
| US9453062B2 (en) | 2011-06-10 | 2016-09-27 | Beijing Hanmi Pharmaceutical Co., Ltd. | Glucose dependent insulinotropic polypeptide analogs, pharmaceutical compositions and use thereof |
| KR101577734B1 (ko) | 2011-06-17 | 2015-12-29 | 한미사이언스 주식회사 | 옥신토모듈린과 면역글로불린 단편을 포함하는 결합체 및 그의 용도 |
| CN103748109A (zh) * | 2011-06-22 | 2014-04-23 | 印第安纳大学研究及科技有限公司 | 胰高血糖素/glp-1受体共同激动剂 |
| SI2723367T1 (sl) | 2011-06-22 | 2017-08-31 | Indiana University Research And Technology Corporation | Koagonisti receptorja glukanona/GLP-1 |
| EP2729493B1 (en) | 2011-07-04 | 2020-06-10 | IP2IPO Innovations Limited | Novel compounds and their effects on feeding behaviour |
| AR088161A1 (es) | 2011-09-23 | 2014-05-14 | Novo Nordisk As | Analogos de glucagon |
| RU2014117678A (ru) | 2011-11-17 | 2015-12-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью |
| TWI689515B (zh) | 2012-05-03 | 2020-04-01 | 丹麥商西蘭製藥公司 | Ｇｉｐ-ｇｌｐ-１雙重促效劑化合物及方法 |
| CN107739409A (zh) | 2012-05-18 | 2018-02-27 | 爱德迪安（北京）生物技术有限公司 | 用于糖尿病治疗的蛋白、蛋白缀合物及其应用 |
| BR112014031671A2 (pt) * | 2012-06-21 | 2018-08-07 | Hoffmann La Roche | análogos de glucagon exibindo atividade de receptor gip |
| JP6311708B2 (ja) * | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | Ｇｉｐ受容体活性を示すグルカゴンアナローグ |
| KR102129235B1 (ko) | 2012-07-23 | 2020-07-06 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| WO2014041375A1 (en) | 2012-09-17 | 2014-03-20 | Imperial Innovations Limited | Peptide analogues of glucagon and glp1 |
| TWI608013B (zh) | 2012-09-17 | 2017-12-11 | 西蘭製藥公司 | 升糖素類似物 |
| GB2505941A (en) * | 2012-09-17 | 2014-03-19 | Imp Innovations Ltd | Peptide analogues of glucagon for the treatment of obesity and diabetes |
| WO2014049610A2 (en) | 2012-09-26 | 2014-04-03 | Cadila Healthcare Limited | Peptides as gip, glp-1 and glucagon receptors triple-agonist |
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| MX372833B (es) | 2012-11-06 | 2020-06-25 | Hanmi Pharm Co Tld | Formulacion liquida del conjugado de proteina que comprende la oxintomodulina y un fragmento de inmunoglobulina. |
| KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
| TWI674270B (zh) | 2012-12-11 | 2019-10-11 | 英商梅迪繆思有限公司 | 用於治療肥胖之升糖素與glp-1共促效劑 |
| LT2934567T (lt) | 2012-12-21 | 2018-09-10 | Sanofi | Eksendino-4 dariniai kaip dvigubi glp1/gip arba trigubi glp1/gip/gliukagono agonistai |
| JP2016512213A (ja) * | 2013-03-14 | 2016-04-25 | メディミューン リミテッド | 肥満の治療のためのペグ化グルカゴン及びｇｌｐ−１コアゴニスト |
| US20160058881A1 (en) * | 2013-03-15 | 2016-03-03 | Indiana University Research And Technology Corporation | Prodrugs with prolonged action |
| US10087221B2 (en) | 2013-03-21 | 2018-10-02 | Sanofi-Aventis Deutschland Gmbh | Synthesis of hydantoin containing peptide products |
| AU2014234314B2 (en) | 2013-03-21 | 2018-02-15 | Sanofi-Aventis Deutschland Gmbh | Synthesis of cyclic imide containing peptide products |
| WO2014161835A1 (en) | 2013-04-03 | 2014-10-09 | Sanofi | Modified blood glucose regulating proteins with altered pharmacological activity profile and preparation thereof |
| MX362275B (es) | 2013-04-18 | 2019-01-10 | Novo Nordisk As | Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico. |
| MA38472B1 (fr) * | 2013-05-28 | 2018-09-28 | Takeda Pharmaceuticals Co | Composé peptidique |
| US9988429B2 (en) | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| US9896495B2 (en) | 2013-10-17 | 2018-02-20 | Zealand Pharma A/S | Acylated glucagon analogues |
| WO2015067715A2 (en) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Gip-glp-1 dual agonist compounds and methods |
| EA035688B1 (ru) | 2013-11-06 | 2020-07-27 | Зилэнд Фарма А/С | Соединения, которые представляют собой тройные агонисты глюкагона, glp-1 и gip |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| WO2015086730A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Non-acylated exendin-4 peptide analogues |
| TW201609797A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／升糖素受體促效劑 |
| AR098614A1 (es) | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Compuesto para el tratamiento de hipoglicemia severa |
| US9963496B2 (en) | 2014-02-18 | 2018-05-08 | Novo Nordisk A/S | Stable glucagon analogues and use for treatment of hypoglycaemia |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| CN106536547A (zh) | 2014-06-04 | 2017-03-22 | 诺和诺德股份有限公司 | 用于医疗用途的glp‑1/胰高血糖素受体共激动剂 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| TWI772252B (zh) * | 2014-09-16 | 2022-08-01 | 南韓商韓美藥品股份有限公司 | 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途 |
| CA2964379C (en) | 2014-10-24 | 2023-08-15 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and glp-1 receptors |
| EP3212218B1 (en) | 2014-10-29 | 2021-06-30 | Zealand Pharma A/S | Gip agonist compounds and methods |
| UA126960C2 (uk) | 2014-12-30 | 2023-03-01 | Ханмі Фарм. Ко., Лтд. | Похідна глюкагону |
| KR102418477B1 (ko) | 2014-12-30 | 2022-07-08 | 한미약품 주식회사 | 글루카곤 유도체 |
| TWI707867B (zh) | 2015-04-16 | 2020-10-21 | 丹麥商西蘭製藥公司 | 醯化之昇糖素類似物 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TWI726889B (zh) | 2015-06-10 | 2021-05-11 | 英商梅迪繆思有限公司 | 蛋白酶抗性之脂化肽 |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| CN108025041A (zh) | 2015-06-30 | 2018-05-11 | 韩美药品株式会社 | 胰高血糖素衍生物和包含其长效缀合物的组合物 |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| US10493125B2 (en) | 2015-12-09 | 2019-12-03 | Merck Sharp & Dohme Corp. | Co-agonists of the glucagon and GLP-1 receptors |
| DK3398961T3 (da) | 2015-12-31 | 2022-08-22 | Hanmi Pharm Ind Co Ltd | Tredobbelt aktivator, der aktiverer glukagon, glp 1 og gip-receptor |
| JP7077237B2 (ja) * | 2016-05-16 | 2022-05-30 | インターシア セラピューティクス，インコーポレイティド | グルカゴン受容体選択的ポリペプチド及びその使用方法 |
| CA3024962A1 (en) | 2016-05-24 | 2017-11-30 | Takeda Pharmaceutical Company Limited | Peptide compound |
| US10078570B2 (en) | 2016-05-26 | 2018-09-18 | International Business Machines Corporation | Determining dynamic statistics based on key value patterns |
| TWI757305B (zh) | 2016-06-29 | 2022-03-11 | 南韓商韓美藥品股份有限公司 | 升糖素衍生物、其接合物、及包含其之組成物、及其醫療用途 |
| TW201833132A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 作為肽類ｇｌｐ１／升糖素／ｇｉｐ三重受體激動劑之新穎化合物 |
| AR110301A1 (es) | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos de receptores de glp1 / glucagón / gip |
| EP3551202B1 (en) | 2016-12-06 | 2024-01-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of enhancing the potency of incretin-based drugs in subjects in need thereof |
| JOP20180028A1 (ar) | 2017-03-31 | 2019-01-30 | Takeda Pharmaceuticals Co | مركب ببتيد |
| CN109836488B (zh) * | 2017-11-24 | 2022-08-23 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的胰高血糖素类似物 |
| ES2928207T3 (es) | 2018-04-10 | 2022-11-16 | Sanofi Aventis Deutschland | Síntesis de lixisenatida con encapuchado |
| KR102793451B1 (ko) | 2018-04-10 | 2025-04-11 | 사노피-아벤티스 도이칠란트 게엠베하 | 고체상으로부터 고체상-결합된 펩타이드를 절단하는 방법 |
| TW202015735A (zh) | 2018-05-30 | 2020-05-01 | 法商賽諾菲公司 | 包含ｇｌｐ－１／升糖素／ｇｉｐ三重受體促效劑、連接子及透明質酸之接合物 |
| US12122815B2 (en) * | 2018-09-24 | 2024-10-22 | Takeda Pharmaceutical Company Limited | GIP receptor agonist peptide compounds and uses thereof |
| JP7350851B2 (ja) | 2018-11-12 | 2023-09-26 | 天津薬物研究院有限公司 | グルカゴン由来ペプチド及びその用途 |
| EP3954701A4 (en) * | 2019-04-11 | 2023-09-06 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | MULTIRECEPTOR AGONIST AND MEDICAL USE THEREOF |
| CN114853908B (zh) | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| EP3842449A1 (en) * | 2019-12-23 | 2021-06-30 | Merck Sharp & Dohme Corp. | Stapled olefin co-agonists of the glucagon and glp-1 receptors |
| CN113493503B (zh) * | 2020-04-08 | 2022-08-05 | 浙江道尔生物科技有限公司 | 一种肠促胰岛素类似物及其制备方法和用途 |
| CN113278060B (zh) * | 2020-05-29 | 2022-03-25 | 东莞云璟生物技术有限公司 | Glp-1/胰高血糖素双重激动剂融合蛋白 |
| PE20231841A1 (es) | 2020-07-22 | 2023-11-21 | Novo Nordisk As | Coagonistas de los receptores glp-1 y gip adecuados para el suministro oral |
| CN112625093B (zh) * | 2020-12-29 | 2022-12-23 | 清远市图微安创科技开发有限公司 | 用于预防和/或治疗非酒精性脂肪肝炎的多肽化合物 |
| TW202330584A (zh) | 2022-01-20 | 2023-08-01 | 丹麥商諾佛 儂迪克股份有限公司 | 前藥及其用途 |
| WO2025141129A1 (en) | 2023-12-28 | 2025-07-03 | Zealand Pharma A/S | Formulations of glucagon-like-peptide 2 (glp-2) analogues and their uses |
| CN119954932B (zh) * | 2025-04-10 | 2025-07-22 | 广州呼吸药物工程技术有限公司 | 一种含β-氨基酸的胰高血糖素类似物或其药学上可接受的盐及其应用 |
Family Cites Families (134)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275152A (en) | 1977-02-03 | 1981-06-23 | Eastman Kodak Company | Hydrolysis of protein-bound cholesterol esters |
| PT83613B (en) | 1985-10-28 | 1988-11-21 | Lilly Co Eli | Process for the selective chemical removal of a protein amino-terminal residue |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| WO1990009395A1 (en) | 1989-02-17 | 1990-08-23 | Coselco Mimotopes Pty. Ltd. | Method for the use and synthesis of peptides |
| CA2073856C (en) | 1990-01-24 | 2002-12-03 | Douglas I. Buckley | Glp-1 analogs useful for diabetes treatment |
| US5545618A (en) | 1990-01-24 | 1996-08-13 | Buckley; Douglas I. | GLP-1 analogs useful for diabetes treatment |
| CA2024855C (en) | 1990-09-07 | 1997-12-09 | Boehringer Ingelheim (Canada) Ltd./ Boehringer Ingelheim (Canada) Ltee | Process and intermediates for producing glucagon |
| JPH04145099A (ja) | 1990-10-05 | 1992-05-19 | Sanwa Kagaku Kenkyusho Co Ltd | Ｇｉｐ様活性を有するポリペプチド誘導体及びその用途 |
| US5510459A (en) | 1991-01-17 | 1996-04-23 | Zymogenetics, Inc. | Glucagon antagonists |
| AU4851393A (en) | 1992-09-11 | 1994-04-12 | Regents Of The University Of Michigan, The | Non-human animal with xenograft of on airway populated by human cells |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5480867A (en) | 1993-12-29 | 1996-01-02 | The Rockefeller University | Glucagon analogs with serine replacements |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| US5869602A (en) | 1995-03-17 | 1999-02-09 | Novo Nordisk A/S | Peptide derivatives |
| DE19530865A1 (de) | 1995-08-22 | 1997-02-27 | Michael Dr Med Nauck | Wirkstoff sowie Mittel zur parenteralen Ernährung |
| CA2243718A1 (en) | 1996-02-06 | 1997-08-14 | Eli Lilly And Company | Diabetes therapy |
| ATE316100T1 (de) | 1996-06-05 | 2006-02-15 | Roche Diagnostics Gmbh | Exendin-analoga, verfahren zu deren herstellung und diese enthaltende arzneimittel |
| IL128828A0 (en) | 1996-09-09 | 2000-01-31 | Zealand Pharmaceuticals As | Peptide prodrugs containing an alpha-hydroxy acid linker |
| UA65549C2 (uk) | 1996-11-05 | 2004-04-15 | Елі Ліллі Енд Компані | Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція |
| AU5518798A (en) | 1996-12-03 | 1998-06-29 | Trustees Of Boston University | Specific antagonists for glucose-dependent insulinotropic polypeptide (gip) |
| IL138214A0 (en) | 1998-03-09 | 2001-10-31 | Zealand Pharmaceuticals As | Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis |
| DE19828113A1 (de) | 1998-06-24 | 2000-01-05 | Probiodrug Ges Fuer Arzneim | Prodrugs von Inhibitoren der Dipeptidyl Peptidase IV |
| US20030236190A1 (en) | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
| US6410508B1 (en) | 1998-10-07 | 2002-06-25 | Med College Georgia Res Inst | Glucose-dependent insulinotropic peptide for use as an osteotropic hormone |
| PL202367B1 (pl) * | 1998-12-07 | 2009-06-30 | Sod Conseils Rech Applic | Związki stanowiące analogi GLP-1, kompozycje zawierające te związki oraz zastosowanie tych związków |
| EP1147094A1 (en) | 1999-01-15 | 2001-10-24 | Novo Nordisk A/S | Non-peptide glp-1 agonists |
| GB0404124D0 (en) | 2004-02-25 | 2004-03-31 | Univ Ulster | Antagonists of GIP |
| WO2000058360A2 (en) | 1999-03-29 | 2000-10-05 | Uutech Limited | Analogs of gastric inhibitory peptide and their use for treatment of diabetes |
| SI1180121T1 (en) | 1999-05-17 | 2004-04-30 | Conjuchem, Inc. | Long lasting insulinotropic peptides |
| WO2001081919A2 (en) | 2000-04-27 | 2001-11-01 | Bionebraska, Inc. | Gastric inhibitory polypeptide diagnostic test for detecting susceptibility to type-2 diabetes, impaired glucose tolerance, or impaired fasting glucose |
| US6677136B2 (en) | 2000-05-03 | 2004-01-13 | Amgen Inc. | Glucagon antagonists |
| JP2004503565A (ja) | 2000-06-14 | 2004-02-05 | サイトヴァックス・バイオテクノロジーズ・インコーポレーテッド | 構造特異的ペプチドを生産するためのコイルドコイル構造的骨格の使用 |
| MXPA02012203A (es) | 2000-06-16 | 2003-06-06 | Lilly Co Eli | Analogos de peptido 1 tipo glucagon. |
| JP2004509079A (ja) | 2000-08-02 | 2004-03-25 | セラテクノロジーズ・インコーポレーテッド | 効力が増大した修飾生体ペプチド |
| US6846831B2 (en) | 2000-08-15 | 2005-01-25 | Cpd, Llc | Method of treating the syndrome of lipodystrophy |
| US6262062B1 (en) | 2000-08-15 | 2001-07-17 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US20020045572A1 (en) | 2000-08-15 | 2002-04-18 | Cpd, Llc | Method of treating the syndrome of type 2 diabetes in humans |
| US6528520B2 (en) | 2000-08-15 | 2003-03-04 | Cpd, Llc | Method of treating the syndrome of coronary heart disease risk factors in humans |
| US7052686B2 (en) | 2000-09-29 | 2006-05-30 | Schering Corporation | Pegylated interleukin-10 |
| US7199217B2 (en) | 2000-12-13 | 2007-04-03 | Eli Lilly And Company | Amidated glucagon-like peptide-1 |
| EP2275117B1 (en) | 2001-07-31 | 2016-10-26 | The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services | GLP-1, exendin-4, peptide analogs and uses thereof |
| EP1572885A2 (en) | 2001-08-08 | 2005-09-14 | Genzyme Corporation | Methods for treating diabetes and other blood sugar disorders |
| EP1432430A4 (en) | 2001-08-28 | 2006-05-10 | Lilly Co Eli | PREMIXTURES OF GLP-1 AND BASALINSULIN |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| US7041646B2 (en) | 2001-10-05 | 2006-05-09 | Bayer Pharmaceuticals Corporation | Methods of treating type 2 diabetes with peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists |
| AR036711A1 (es) | 2001-10-05 | 2004-09-29 | Bayer Corp | Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico |
| US6864069B2 (en) | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
| AU2002348469B2 (en) | 2001-10-18 | 2008-03-13 | Bristol-Myers Squibb Company | Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions |
| US7179788B2 (en) | 2001-10-19 | 2007-02-20 | Eli Lilly And Company | Biphasic mixtures of GLP-1 and insulin |
| WO2003059378A2 (en) | 2001-12-29 | 2003-07-24 | Novo Nordisk A/S | Combined use of a glp-1 compound and another drug for treating dyslipidemia |
| WO2003058203A2 (en) | 2002-01-08 | 2003-07-17 | Eli Lilly And Company | Extended glucagon-like peptide-1 analogs |
| US20030232761A1 (en) | 2002-03-28 | 2003-12-18 | Hinke Simon A. | Novel analogues of glucose-dependent insulinotropic polypeptide |
| EP1575490A4 (en) | 2002-06-04 | 2007-08-08 | Lilly Co Eli | MODIFIED ANALOGUES OF GLUCAGON-LIKE PEPTIDE-1 (GLP-1) |
| AU2003237933A1 (en) | 2002-06-11 | 2003-12-22 | Cellartis Ab | Use of compounds having gip activity for the treatment of disorders associated with abnormal loss of cells and/or for the treatment of obesity |
| US20040029805A1 (en) | 2002-06-15 | 2004-02-12 | Wolfe M. Michael | Prevention and treatment of nonalcoholic fatty liver disease (NAFLD) by antagonism of the receptor to glucose-dependent insulinotropic polypeptide (GIP) |
| EP1539210A4 (en) | 2002-09-06 | 2006-06-07 | Bayer Pharmaceuticals Corp | GLP-1 RECEPTOR MODIFIED AGONISTS AND THEIR PHARMACOLOGICAL METHODS OF USE |
| US7192922B2 (en) | 2002-11-19 | 2007-03-20 | Allegheny-Singer Research Institute | Method of treating left ventricular dysfunction |
| AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| WO2004067548A2 (en) | 2003-01-31 | 2004-08-12 | Theratechnologies Inc. | Chemically modified metabolites of regulatory peptides and methods of producing and using same |
| EP1626981A4 (en) | 2003-03-04 | 2006-11-22 | Biorexis Pharmaceutical Corp | PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE |
| PL1605897T3 (pl) | 2003-03-19 | 2012-12-31 | Lilly Co Eli | Związki będące połączeniem GLP-1 z poli(glikolem etylenowym) |
| EP1620118B1 (en) | 2003-04-08 | 2014-06-18 | Yeda Research And Development Co., Ltd. | Reversible pegylated drugs |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| WO2004103390A2 (en) | 2003-05-15 | 2004-12-02 | Trustees Of Tufts College | Stable analogs of peptide and polypeptide therapeutics |
| WO2004105781A2 (en) | 2003-06-03 | 2004-12-09 | Novo Nordisk A/S | Stabilized pharmaceutical peptide compositions |
| JP2007524592A (ja) | 2003-06-03 | 2007-08-30 | ノボ・ノルデイスク・エー／エス | 安定化された薬学的ペプチド組成物 |
| PL1641823T3 (pl) | 2003-06-12 | 2012-02-29 | Lilly Co Eli | Białka fuzyjne analogu GLP-1 |
| WO2004111078A2 (en) | 2003-06-18 | 2004-12-23 | Theratechnologies Inc. | Compounds that modulate the glucagon response and uses thereof |
| WO2005027978A2 (en) | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
| US7364875B2 (en) | 2003-10-30 | 2008-04-29 | Cresent Innovations, Inc. | Method for producing medical and commercial grade poly-gamma-glutamic acid of high molecular weight |
| WO2005058954A1 (en) | 2003-12-18 | 2005-06-30 | Novo Nordisk A/S | Novel glp-1 compounds |
| US20060286129A1 (en) | 2003-12-19 | 2006-12-21 | Emisphere Technologies, Inc. | Oral GLP-1 formulations |
| US20080318837A1 (en) | 2003-12-26 | 2008-12-25 | Nastech Pharmaceutical Company Inc. | Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide |
| US7442682B2 (en) * | 2004-10-19 | 2008-10-28 | Nitto Denko Corporation | Transepithelial delivery of peptides with incretin hormone activities |
| US8263545B2 (en) * | 2005-02-11 | 2012-09-11 | Amylin Pharmaceuticals, Inc. | GIP analog and hybrid polypeptides with selectable properties |
| AU2006213607A1 (en) | 2005-02-11 | 2006-08-17 | Amylin Pharmaceuticals, Llc | GIP analog and hybrid polypeptides with selectable properties |
| WO2006097536A2 (en) | 2005-03-18 | 2006-09-21 | Novo Nordisk A/S | Dimeric peptide agonists of the glp-1 receptor |
| WO2006121904A1 (en) | 2005-05-06 | 2006-11-16 | Bayer Pharmaceuticals Corporation | Glucose-dependent insulinotropic polypeptide (gip) receptor agonists and their pharmacological methods of use |
| CN101166545B (zh) | 2005-05-13 | 2011-06-15 | 伊莱利利公司 | Glp-1聚乙二醇化的化合物 |
| PT1891105E (pt) | 2005-06-13 | 2012-06-27 | Imp Innovations Ltd | Análogos de oxintomodulina e seus efeitos sobre o comportamento da alimentação |
| AU2006279680B2 (en) | 2005-08-11 | 2012-12-06 | Amylin Pharmaceuticals, Llc | Hybrid polypeptides with selectable properties |
| AU2006289259A1 (en) | 2005-09-08 | 2007-03-15 | Uutech Limited | Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function |
| CA2622069A1 (en) | 2005-09-08 | 2007-03-15 | Uutech Limited | Treatment of diabetes related obesity |
| CN101534846B (zh) | 2005-11-07 | 2014-11-05 | 印第安纳大学研究及科技有限公司 | 显示生理学溶解性和稳定性的胰高血糖素类似物 |
| US7928058B2 (en) | 2006-02-22 | 2011-04-19 | Merck Sharp & Dohme Corp. | Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition |
| EP1996224B1 (en) | 2006-03-15 | 2012-11-07 | Novo Nordisk A/S | Mixtures of amylin and insulin |
| WO2007109354A2 (en) | 2006-03-21 | 2007-09-27 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of using same |
| MX2008013304A (es) | 2006-04-20 | 2008-10-27 | Amgen Inc | Compuestos de peptido 1 tipo glucagon. |
| US8475972B2 (en) | 2006-05-01 | 2013-07-02 | Honda Motor Co., Ltd. | Fuel cell |
| WO2008022015A2 (en) | 2006-08-11 | 2008-02-21 | Trustees Of Tufts College | Retro-inverso incretin analogues, and methods of use thereof |
| CA2660835A1 (en) | 2006-08-17 | 2008-02-21 | Amylin Pharmaceuticals, Inc. | Dpp-iv resistant gip hybrid polypeptides with selectable propperties |
| EP2057189B1 (en) | 2006-08-25 | 2013-03-06 | Novo Nordisk A/S | Acylated exendin-4 compounds |
| CA2663083A1 (en) | 2006-09-08 | 2008-03-13 | Ambrx, Inc. | Modified human plasma polypeptide or fc scaffolds and their uses |
| EP2102355B1 (en) | 2006-12-14 | 2016-03-02 | Bolder Biotechnology, Inc. | Long acting proteins and peptides and methods of making and using the same |
| JP5890085B2 (ja) | 2007-01-05 | 2016-03-22 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | 生理学的ｐＨの緩衝液中で向上した溶解度を示すグルカゴン類縁体 |
| US8454971B2 (en) * | 2007-02-15 | 2013-06-04 | Indiana University Research And Technology Corporation | Glucagon/GLP-1 receptor co-agonists |
| DK2158214T3 (da) * | 2007-06-15 | 2011-12-05 | Zealand Pharma As | Glukagonanaloger |
| US8895694B2 (en) | 2007-09-05 | 2014-11-25 | Novo Nordisk A/S | Glucagon-Like Peptide-1 derivatives and their pharmaceutical use |
| EP2190873B1 (en) | 2007-09-05 | 2015-07-22 | Novo Nordisk A/S | Truncated glp-1 derivatives and their therapeutical use |
| EP2650006A1 (en) | 2007-09-07 | 2013-10-16 | Ipsen Pharma S.A.S. | Analogues of exendin-4 and exendin-3 |
| EP2036539A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Stable formulations of amylin and its analogues |
| EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
| CN101854948A (zh) | 2007-09-11 | 2010-10-06 | 诺沃-诺迪斯克有限公司 | 含有胰岛淀粉样多肽类和长效胰岛素的合剂 |
| EP2214691B1 (en) | 2007-10-30 | 2015-09-30 | Indiana University Research and Technology Corporation | Compounds exhibiting glucagon antagonist and glp-1 agonist activity |
| AU2008318986B2 (en) * | 2007-10-30 | 2014-12-04 | Indiana University Research And Technology Corporation | Glucagon antagonists |
| WO2009059278A1 (en) | 2007-11-02 | 2009-05-07 | Centocor, Inc. | Semi-synthetic glp-1 peptide-fc fusion constructs, methods and uses |
| WO2009099763A1 (en) | 2008-01-30 | 2009-08-13 | Indiana University Research And Technology Corporation | Ester-based peptide prodrugs |
| JP5588354B2 (ja) | 2008-02-01 | 2014-09-10 | アセンディス ファーマ エー／エス | 自己切断可能なリンカーを含むプロドラッグ |
| WO2009155257A1 (en) | 2008-06-17 | 2009-12-23 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability physiological ph buffers |
| AR072159A1 (es) * | 2008-06-17 | 2010-08-11 | Univ Indiana Res & Tech Corp | Analogos de glucagon, basados en (peptido insulinotropico dependiente de la glucosa) gip para el tratamiento de trastornos metabolicos y obesidad |
| EP2676673B1 (en) | 2008-06-17 | 2016-11-16 | Indiana University Research and Technology Corporation | Glucagon/glp-1 receptor co-agonists |
| US20110245164A1 (en) | 2008-12-19 | 2011-10-06 | Indiana University Research And Technology Corporation | Yl-based insulin-like growth factors exhibiting high activity at the insulin receptor |
| WO2010071807A1 (en) | 2008-12-19 | 2010-06-24 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| CA2744558A1 (en) | 2008-12-19 | 2010-07-15 | Indiana University Research And Technology Corporation | Amide-based insulin prodrugs |
| CN102300580A (zh) | 2008-12-19 | 2011-12-28 | 印第安纳大学研究及科技有限公司 | 二肽连接的药剂 |
| WO2010096052A1 (en) | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| IN2012DN00377A (enExample) | 2009-06-16 | 2015-08-21 | Univ Indiana Res & Tech Corp | |
| EP2512503A4 (en) | 2009-12-18 | 2013-08-21 | Univ Indiana Res & Tech Corp | COAGONISTS OF GLUCAGON / GLP-1 RECEPTOR |
| AR079345A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina |
| AR079344A1 (es) | 2009-12-22 | 2012-01-18 | Lilly Co Eli | Analogo peptidico de oxintomodulina, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para tratar diabetes no insulinodependiente y/u obesidad |
| IN2012DN06437A (enExample) | 2010-01-27 | 2015-10-09 | Univ Indiana Res & Tech Corp | |
| AR080592A1 (es) | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| WO2011143208A1 (en) | 2010-05-13 | 2011-11-17 | Indiana University Research And Technology Corporation | Glucagon superfamily peptides exhibiting g protein-coupled receptor activity |
| KR20130062931A (ko) | 2010-05-13 | 2013-06-13 | 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 | 핵 호르몬 수용체 활성을 나타내는 글루카곤 슈퍼패밀리 펩티드 |
| RU2013102991A (ru) | 2010-06-24 | 2014-08-10 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Связанные с дипептидом лекарственные средства |
| US8778872B2 (en) | 2010-06-24 | 2014-07-15 | Indiana University Research And Technology Corporation | Amide based glucagon superfamily peptide prodrugs |
| WO2011163473A1 (en) | 2010-06-25 | 2011-12-29 | Indiana University Research And Technology Corporation | Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers |
| PH12013501215A1 (en) | 2010-12-22 | 2013-11-18 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
| JP2012194860A (ja) | 2011-03-17 | 2012-10-11 | Murata Mach Ltd | 走行車 |
| SI2723367T1 (sl) | 2011-06-22 | 2017-08-31 | Indiana University Research And Technology Corporation | Koagonisti receptorja glukanona/GLP-1 |
| CN103748109A (zh) | 2011-06-22 | 2014-04-23 | 印第安纳大学研究及科技有限公司 | 胰高血糖素/glp-1受体共同激动剂 |
| RU2014117678A (ru) | 2011-11-17 | 2015-12-27 | Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн | Пептиды глюкагонового суперсемейства, обладающие глюкокортикоидной рецепторной активностью |
| JP6311708B2 (ja) | 2012-06-21 | 2018-04-18 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ | Ｇｉｐ受容体活性を示すグルカゴンアナローグ |
| TW201402611A (zh) | 2012-06-21 | 2014-01-16 | Univ Indiana Res & Tech Corp | 具有改變之ｆｃ效應子功能之腸促胰島素受體配體多肽ｆｃ區融合多肽及結合物 |
-
2010
- 2010-06-16 IN IN377DEN2012 patent/IN2012DN00377A/en unknown
- 2010-06-16 CA CA2765026A patent/CA2765026A1/en not_active Abandoned
- 2010-06-16 BR BRPI1014508A patent/BRPI1014508A2/pt not_active IP Right Cessation
- 2010-06-16 PE PE2011002102A patent/PE20120914A1/es not_active Application Discontinuation
- 2010-06-16 JP JP2012516264A patent/JP5887265B2/ja not_active Expired - Fee Related
- 2010-06-16 MX MX2011013625A patent/MX2011013625A/es not_active Application Discontinuation
- 2010-06-16 US US13/378,001 patent/US9150632B2/en not_active Expired - Fee Related
- 2010-06-16 CN CN201080027026.5A patent/CN102459325B/zh not_active Expired - Fee Related
- 2010-06-16 RU RU2012101274/10A patent/RU2012101274A/ru not_active Application Discontinuation
- 2010-06-16 WO PCT/US2010/038825 patent/WO2010148089A1/en not_active Ceased
- 2010-06-16 KR KR20127000871A patent/KR20120087875A/ko not_active Ceased
- 2010-06-16 AU AU2010260058A patent/AU2010260058B2/en not_active Ceased
- 2010-06-16 EP EP10790117.5A patent/EP2443146B1/en not_active Not-in-force
- 2010-06-16 SG SG2011092772A patent/SG176858A1/en unknown
- 2010-06-17 TW TW099119633A patent/TWI549687B/zh not_active IP Right Cessation
-
2011
- 2011-12-08 IL IL216881A patent/IL216881A/en not_active IP Right Cessation
- 2011-12-15 CL CL2011003173A patent/CL2011003173A1/es unknown
-
2015
- 2015-08-31 US US14/840,580 patent/US9790263B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010148089A1 (en) | 2010-12-23 |
| US9790263B2 (en) | 2017-10-17 |
| TWI549687B (zh) | 2016-09-21 |
| TW201103556A (en) | 2011-02-01 |
| CL2011003173A1 (es) | 2012-05-25 |
| MX2011013625A (es) | 2012-01-20 |
| RU2012101274A (ru) | 2013-07-27 |
| US20160052989A1 (en) | 2016-02-25 |
| EP2443146A4 (en) | 2012-11-21 |
| AU2010260058A1 (en) | 2012-02-02 |
| AU2010260058B2 (en) | 2015-09-24 |
| PE20120914A1 (es) | 2012-08-22 |
| EP2443146A1 (en) | 2012-04-25 |
| IL216881A0 (en) | 2012-02-29 |
| KR20120087875A (ko) | 2012-08-07 |
| CN102459325A (zh) | 2012-05-16 |
| IN2012DN00377A (enExample) | 2015-08-21 |
| JP5887265B2 (ja) | 2016-03-16 |
| BRPI1014508A2 (pt) | 2016-04-05 |
| CA2765026A1 (en) | 2010-12-23 |
| HK1169998A1 (en) | 2013-02-15 |
| SG176858A1 (en) | 2012-02-28 |
| CN102459325B (zh) | 2015-03-25 |
| EP2443146B1 (en) | 2016-10-05 |
| US9150632B2 (en) | 2015-10-06 |
| US20120172295A1 (en) | 2012-07-05 |
| JP2012530145A (ja) | 2012-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL216881A0 (en) | Gip receptor-active glucagon compounds | |
| ZA201104592B (en) | Glucagon analogues | |
| IL213478A0 (en) | Glucagon analogues | |
| ZA201104591B (en) | Glucagon analogues | |
| IL213477A0 (en) | Glucagon analogues | |
| GB0907425D0 (en) | Compounds | |
| EP2393493A4 (en) | LINKS | |
| GB0907515D0 (en) | Compounds | |
| GB0919194D0 (en) | Compounds | |
| GB0915892D0 (en) | Compounds | |
| GB0905641D0 (en) | Compounds | |
| GB0909671D0 (en) | Compounds | |
| IL219336A0 (en) | Metl-granulated cinacalcet | |
| GB0909672D0 (en) | Compounds | |
| AP2909A (en) | Pyrazinoisoquinoline Compounds | |
| EP2443115A4 (en) | COMPOUNDS | |
| GB0908941D0 (en) | Compounds | |
| GB0906853D0 (en) | Compounds | |
| GB0905054D0 (en) | Compounds | |
| GB0903492D0 (en) | Compounds | |
| GB0910008D0 (en) | Compounds | |
| GB0902796D0 (en) | Compounds | |
| GB0904729D0 (en) | Compounds | |
| GB0913753D0 (en) | Compounds | |
| GB0904746D0 (en) | Compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |